Transmedics

TransMedics to Participate in the 41st Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Wednesday, December 21, 2022
Transplant, Transmedics, Patient, Lung, Heart, Liver failure, Perfusion, Conference, Medical device, Dentistry

ANDOVER, Mass., Dec. 21, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will present at the upcoming 41st Annual J.P. Morgan Healthcare Conference.

Key Points: 
  • ANDOVER, Mass., Dec. 21, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will present at the upcoming 41st Annual J.P. Morgan Healthcare Conference.
  • The presentation will take place on Wednesday, January 11, 2023, at 5:15 p.m. Pacific Standard Time / 8:15 p.m. Eastern Standard Time.
  • TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation.
  • Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.

TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Retrieved on: 
Monday, November 7, 2022
Employment, Transmedics, Nasdaq, Perfusion, Company, Director, Heart, Transplant, Financial compensation, Liver failure, Patient, Lung, NASDAQ, Health insurance

The options were approved by the Compensation Committee of the TransMedics Board of Directors and were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the TransMedics Group, Inc. Inducement Plan.

Key Points: 
  • The options were approved by the Compensation Committee of the TransMedics Board of Directors and were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the TransMedics Group, Inc. Inducement Plan.
  • TransMedics granted non-qualified stock options to six new employees to purchase 138,400 shares of TransMedics' common stock in the aggregate.
  • The options have a 10-year term and are subject to the terms of the TransMedics Group, Inc. Inducement Plan.
  • TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation.

TransMedics Reports Third Quarter 2022 Financial Results

Retrieved on: 
Thursday, November 3, 2022
Company, Liver failure, Research, Growth, Heart, Investment, Perfusion, GAAP, Information technology, FDA, Conference, Vaccination, COVID-19, Nasdaq, Marketing, National, Transplant, OCS, Lung, NOP, U.S. Securities and Exchange Commission, Clinical trial, Environment, Surgeon, Transmedics, Union, Technology, Contra, Security (finance), SEC, Patient, MD, Video game, Pharmaceutical industry

ANDOVER, Mass., Nov. 3, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended September 30, 2022.

Key Points: 
  • Net revenue of $25.7 million in the third quarter of 2022, a 378% increase compared to the third quarter of 2021 and a 25% increase compared to the second quarter of 2022.
  • Net revenue for the third quarter of 2022 was $25.7 million, a 378% increase compared to $5.4 million in the third quarter of 2021.
  • Operating expenses for the third quarter of 2022 were $23.7 million, compared to $15.5 million in the third quarter of 2021 and compared to $24.1 million in the second quarter or 2022.
  • Net loss for the third quarter of 2022 was $7.4 million, compared to $13.0 million in the third quarter of 2021.

TransMedics to Report Third Quarter 2022 Financial Results on November 3, 2022

Retrieved on: 
Thursday, October 20, 2022
Perfusion, Lung, Patient, Transmedics, Liver failure, Heart, Conference, Nasdaq, Transplant

ANDOVER, Mass., Oct. 20, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the third quarter of 2022 after market close on Thursday, November 3, 2022.

Key Points: 
  • ANDOVER, Mass., Oct. 20, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the third quarter of 2022 after market close on Thursday, November 3, 2022.
  • The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m.
  • A live and archived webcast of the event will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com/ .
  • TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation.

CIBC Innovation Banking Provides $60 Million Debt Financing to TransMedics Group Inc.

Retrieved on: 
Thursday, September 15, 2022
Surgery, Medical Supplies, Finance, Hospitals, Venture Capital, Banking, Health Technology, Professional Services, Health, MD, Perfusion, Transmedics, Organ care system, OCS, Patient, IPO, Liver failure, Lung, Heart, Health care, Transplant, Organ transplantation, Dentistry

CIBC Innovation Banking is pleased to announce a new debt financing for Massachusetts-based TransMedics Group, Inc. ("TransMedics"), a market leading medical technology company that focuses on organ transplant therapy for patients with end-stage lung, heart and liver failure.

Key Points: 
  • CIBC Innovation Banking is pleased to announce a new debt financing for Massachusetts-based TransMedics Group, Inc. ("TransMedics"), a market leading medical technology company that focuses on organ transplant therapy for patients with end-stage lung, heart and liver failure.
  • TransMedics plans to use the incremental growth capital to accelerate its commercial momentum, helping to grow transplant volume and improve clinical outcomes.
  • "We look forward to working with CIBC Innovation Banking long-term as we continue to grow our market presence."
  • CIBC Innovation Banking is proud to support TransMedics in its pursuit to transform the standard of care for organ transplantation, said Joe Hammer, Co-Head North American Life Science and Healthcare, CIBC Innovation Banking.

TransMedics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

Retrieved on: 
Monday, August 29, 2022
Morgan Stanley, Perfusion, Lung, Sheraton New York Times Square Hotel, Liver failure, Transplant, Heart, Transmedics, Conference, Nasdaq, Patient, Medical device, Dentistry

ANDOVER, Mass., Aug. 29, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will participate in a fireside chat at the upcoming Morgan Stanley 20th Annual Global Healthcare Conference at the Sheraton New York.

Key Points: 
  • ANDOVER, Mass., Aug. 29, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will participate in a fireside chat at the upcoming Morgan Stanley 20th Annual Global Healthcare Conference at the Sheraton New York.
  • The fireside chat will take place on Monday, September 12, 2022, at 11:40 a.m. Eastern Time.
  • TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation.
  • Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.

TransMedics to Present at the Canaccord Genuity 42nd Annual Growth Conference

Retrieved on: 
Tuesday, July 26, 2022
Nasdaq, Heart, Perfusion, Conference, Lung, Transmedics, Canaccord Genuity, Transplant, Patient, Liver failure, Medical device, Dentistry

ANDOVER, Mass., July 26, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will present at the upcoming Canaccord Genuity 42nd Annual Growth Conference at the InterContinental Boston Hotel.

Key Points: 
  • ANDOVER, Mass., July 26, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will present at the upcoming Canaccord Genuity 42nd Annual Growth Conference at the InterContinental Boston Hotel.
  • Management is scheduled to present on Wednesday, August 10, 2022, at 8:00 a.m. Eastern Standard Time.
  • TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation.
  • Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.

TransMedics to Report Second Quarter 2022 Financial Results on August 1, 2022

Retrieved on: 
Monday, July 18, 2022
Transplant, Transmedics, Lung, Patient, Liver failure, Conference, Heart, Perfusion, Nasdaq, Dentistry

ANDOVER, Mass., July 18, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the second quarter of 2022 after market close on Monday, August 1, 2022.

Key Points: 
  • ANDOVER, Mass., July 18, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the second quarter of 2022 after market close on Monday, August 1, 2022.
  • The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m.
  • A live and archived webcast of the event will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com/ .
  • TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation.

TransMedics Receives FDA PMA Approval of OCS™ DCD Heart Indication

Retrieved on: 
Thursday, April 28, 2022
Surgeon, International Society for Heart and Lung Transplantation, U.S. Securities and Exchange Commission, Duke University Hospital, Heart transplantation, Patient, Annual report, Nasdaq, Risk, FDA, OCS, Annual general meeting, CAP, Transmedics, Food, Technology, Information technology, Traction, Vaccination, Brain death, MD, DCD, Achievement, Transplant, Security (finance), Marketing, PMA, Heart, International Society, Research, Coronavirus, Lung, SEC, Liver failure, Environment, Regulation of tobacco by the U.S. Food and Drug Administration, Lung transplantation, Perfusion, Form 10-K, DBD, Medical device, Pharmaceutical industry

The landmark approval stands to significantly expand the pool of eligible donor hearts in the United States and follows FDA PMA approval of the OCS Heart System for use with organs from donors after brain death (DBD) received in September 2021.

Key Points: 
  • The landmark approval stands to significantly expand the pool of eligible donor hearts in the United States and follows FDA PMA approval of the OCS Heart System for use with organs from donors after brain death (DBD) received in September 2021.
  • The OCS Heart System is now approved withthe extended clinical indication forex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death (DCD) hearts.This indication is based on the results of the OCS DCD Heart Trial and the associated Continued Access Protocol (CAP).
  • "The FDA's approval of the OCS for DCD donor hearts is the natural progression from the prior approval of the device for extended criteria brain dead donors, supported by the excellent results from the U.S. DCD trial," said Dr. Jacob Schroder, surgical director of heart transplantation at Duke University Medical Center and the principal investigator for the OCS DCD Heart Trial.
  • With OCS we will be able to expand access to this life saving therapy to more end-stage heart failure patients."

TransMedics to Report First Quarter 2022 Financial Results on May 3, 2022

Retrieved on: 
Tuesday, April 19, 2022
Conference, Transplant, Heart, Nasdaq, Transmedics, Liver failure, Patient, Perfusion, Lung, Dentistry

ANDOVER, Mass., April 19, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the first quarter of 2022 after market close on Tuesday, May 3, 2022.

Key Points: 
  • ANDOVER, Mass., April 19, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the first quarter of 2022 after market close on Tuesday, May 3, 2022.
  • The TransMedics management team will host a corresponding conference call beginning at 5:00 p.m.
  • A live and archived webcast of the event will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com/ .
  • TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation.